Patents by Inventor Linda C. Foster
Linda C. Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030215512Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier.Type: ApplicationFiled: April 14, 2003Publication date: November 20, 2003Inventors: Linda C. Foster, Mei-chang Kuo, Shelia R. Billingsley
-
Publication number: 20030185765Abstract: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.Type: ApplicationFiled: March 14, 2003Publication date: October 2, 2003Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Publication number: 20030129141Abstract: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.Type: ApplicationFiled: January 31, 2003Publication date: July 10, 2003Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Publication number: 20030130176Abstract: This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.Type: ApplicationFiled: May 29, 2002Publication date: July 10, 2003Inventors: David B. Bennett, Kirsten M. Cabot, Linda C. Foster, David Lechuga-Ballesteros, John S. Patton, Trixie K. Tan
-
Patent number: 6589560Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions.Type: GrantFiled: June 11, 2001Date of Patent: July 8, 2003Assignee: Nektar TherapeuticsInventors: Linda C. Foster, Mei-chang Kuo, Shelia R. Billingsley
-
Patent number: 6582729Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.Type: GrantFiled: August 15, 2000Date of Patent: June 24, 2003Assignee: Naktar TherapeuticsInventors: Mohammad Eljamal, John S. Patton, Linda C. Foster, Robert M. Platz
-
Publication number: 20030072718Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: ApplicationFiled: September 18, 2002Publication date: April 17, 2003Inventors: Robert M. Platz, Shigenobu Kimura, Yu-Jchiro Satoh, Linda C. Foster
-
Publication number: 20030035778Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: ApplicationFiled: September 17, 2002Publication date: February 20, 2003Inventors: Robert Platz, Shigenobu Kimura, Yu-Ichiro Satoh, Linda C. Foster
-
Patent number: 6514496Abstract: This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.Type: GrantFiled: March 21, 2000Date of Patent: February 4, 2003Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Patent number: 6479049Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: GrantFiled: February 17, 2000Date of Patent: November 12, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
-
Publication number: 20020141945Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier.Type: ApplicationFiled: June 11, 2001Publication date: October 3, 2002Inventors: Linda C. Foster, Mei-Chang Kuo, Shelia R. Billingsley
-
Publication number: 20020117170Abstract: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.Type: ApplicationFiled: February 8, 2002Publication date: August 29, 2002Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Patent number: 6413547Abstract: This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.Type: GrantFiled: February 11, 1999Date of Patent: July 2, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: David B. Bennett, Kirsten M. Cabot, Linda C. Foster, David Lechuga-Ballesteros, John S. Patton, Trixie K. Tan
-
Patent number: 6309671Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions.Type: GrantFiled: October 14, 1997Date of Patent: October 30, 2001Assignee: Inhale Therapeutic SystemsInventors: Linda C. Foster, Mei-chang Kuo, Shelia R. Billingsley
-
Patent number: 6258341Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage from having a moisture barrier, in combination with appropriate labelling instructions.Type: GrantFiled: October 17, 1996Date of Patent: July 10, 2001Assignee: Inhale Therapeutic Systems, Inc.Inventors: Linda C. Foster, Mei-chang Kuo, Sheila R. Billingsley
-
Patent number: 6231851Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: GrantFiled: July 14, 1997Date of Patent: May 15, 2001Assignee: Inhale Therapeutic SystemsInventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
-
Patent number: 6187344Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.Type: GrantFiled: July 31, 1997Date of Patent: February 13, 2001Assignee: Inhale Therapeutic SystemsInventors: Mohammed Eljamal, John S. Patton, Linda C. Foster, Robert M. Platz
-
Patent number: 6165463Abstract: This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.Type: GrantFiled: June 1, 1999Date of Patent: December 26, 2000Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Patent number: 6123936Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: GrantFiled: November 22, 1999Date of Patent: September 26, 2000Assignee: Inhale Therapeutics Systems, Inc.Inventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
-
Patent number: 6019968Abstract: This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.Type: GrantFiled: October 16, 1997Date of Patent: February 1, 2000Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal